ADIAL PHARMACEUTICALS, INC. — Director's Dealing 2018

Aug 2, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ADIAL PHARMACEUTICALS, INC. (ADIL)
CIK: 0001513525
Period of Report: 2018-07-31

Reporting Person: Goodman Tony (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-07-31	Common Stock	P	7000	—	Acquired	8755	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-31	Warrant to purchase common stock	$6.25	P	7000	Acquired	2023-07-31	Common Stock (7000)	Direct

Footnotes

F1: On July 31, 2018, the reporting person purchased 7,000 units (the "Units") in the initial public offering (the "IPO") of Adial Pharmaceuticals, Inc. (the "Company") at a price of $5.00 per Unit, which corresponds to a price of $4.99 per share of common stock and $0.01 per warrant). Each Unit consisted of one share of common stock and a warrant to purchase one share of common stock. The shares of common stock and warrants were immediately separable upon issuance of the Units in the IPO.